Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6092039 | 0.90 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL6094788 | 0.90 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL5643747 | 0.88 | PTGS2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL5769502 | 0.88 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL5646523 | 0.86 | PTGS2 (0.52) | PTGS2PTGS1 | |
| SCHEMBL16550503 | 0.83 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL5644984 | 0.83 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL5645007 | 0.82 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL5667609 | 0.82 | PTGS2 (0.76) | PTGS2PTGS1 | |
| SCHEMBL5649455 | 0.81 | PTGS2 (0.58) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539142-A2 | USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER S DISEASE | Pharmacia Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1463500-A1 | USE OF COX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR THE TREATMENT OF PAPILLOMA VIRUS INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-06 | — | — | EP | claimed |
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | claimed |
| WO-2004014367-A2 | USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PHARMACIA CORPORATION (US) | 2004-02-19 | — | — | WO | claimed |
| WO-2003059347-A1 | USE OF COX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR THE TREATMENT OF PAPILLOMA VIRUS INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | claimed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| EP-3509604-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | Trustees of Tufts College (US) | 2019-07-17 | — | — | EP | disclosed |
| WO-2018187698-A2 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE (US) | 2018-10-11 | — | — | WO | disclosed |
| WO-2018049027-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE (US) | 2018-03-15 | — | — | WO | disclosed |
| EP-1608361-A4 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND 5-HT1B/1D AGONISTS FOR THE TREATMENT AND PREVENTION OF MIGRAINE | PHARMACIA CORP (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1653940-A1 | THERAPEUTIC COMBINATION OF A COX-2 INHIBITOR AND AN AROMATASE INHIBITOR | Pharmacia Corporation (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1608361-A2 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND 5-HT1B/1D AGONISTS FOR THE TREATMENT AND PREVENTION OF MIGRAINE | Pharmacia Corporation (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1463495-A4 | AGENTS AND METHODS FOR TREATMENT OF CANCER | PHARMACIA CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2003101380-A2 | AMYOTROPHIC LATERAL SCLEROSIS TREATMENT WITH CYCLOOXYGENASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003092691-A1 | COMBINATION OF CYCLOOXYGENASE-2 INHIBITORS AND THALIDOMIDE FOR THE TREATMENT OF NEOPLASIA | PHARMACIA COPORATION (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003088958-A2 | COMBINATIONS OF COX-2 INHIBITORS AND OTHER AGENTS FOR THE TREATMENT OF PARKINSON’S DISEASE | PHARMACIA CORPORATION (US) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003088959-A2 | TREATMENT OF PARKINSON'S DISEASE WITH CYCLOOXYGENASE-2 (COX 2) INHIBITOR(S) | PHARMACIA CORPORATION (US) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003059347-A1 | USE OF COX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR THE TREATMENT OF PAPILLOMA VIRUS INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002076395-A2 | AGENTS AND METHODS FOR TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |